{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Attenuvax", "query": { "intervention": "Attenuvax" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Attenuvax&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T20:21:45.501Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06771674", "title": "Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hookipa Biotech GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 662, "start_date": "2024-06-05", "completion_date": "2025-02-28", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-09-05T20:21:45.501Z", "location_count": 1, "location_summary": "Dublin, Ohio", "locations": [ { "city": "Dublin", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06771674" }, { "nct_id": "NCT03239873", "title": "Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Varicella" ], "interventions": [ { "name": "VARIVAX® PE34 Process", "type": "BIOLOGICAL" }, { "name": "VARIVAX® 2016 Commercial Process", "type": "BIOLOGICAL" }, { "name": "M-M-R II®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "23 Months", "sex": "ALL", "summary": "12 Months to 23 Months" }, "enrollment_count": 600, "start_date": "2017-10-17", "completion_date": "2019-04-02", "has_results": true, "last_update_posted_date": "2021-01-27", "last_synced_at": "2026-09-05T20:21:45.501Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03239873" }, { "nct_id": "NCT01681992", "title": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Measles", "Mumps", "Rubella", "Measles-Mumps-Rubella Vaccine" ], "interventions": [ { "name": "Priorix", "type": "BIOLOGICAL" }, { "name": "M-M-R II", "type": "BIOLOGICAL" }, { "name": "Varivax", "type": "BIOLOGICAL" }, { "name": "Havrix", "type": "BIOLOGICAL" }, { "name": "Prevnar 13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 4538, "start_date": "2012-10-10", "completion_date": "2015-08-18", "has_results": true, "last_update_posted_date": "2021-01-07", "last_synced_at": "2026-09-05T20:21:45.501Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01681992" }, { "nct_id": "NCT07162480", "title": "Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenoid Cystic Carcinoma" ], "interventions": [ { "name": "P-Sam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2026-04-29", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-05T20:21:45.501Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07162480" }, { "nct_id": "NCT05743270", "title": "Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "RP3", "type": "BIOLOGICAL" }, { "name": "CCRT(concurrent chemoradiation therapy)", "type": "OTHER" }, { "name": "carboplatin and paclitaxel", "type": "OTHER" }, { "name": "nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-01-30", "completion_date": "2026-06-01", "has_results": false, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-09-05T20:21:45.501Z", "location_count": 12, "location_summary": "La Jolla, California • Los Angeles, California • Iowa City, Iowa + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743270" }, { "nct_id": "NCT00289783", "title": "Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Haemophilus Influenzae Type b", "Neisseria Meningitidis" ], "interventions": [ { "name": "GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine", "type": "BIOLOGICAL" }, { "name": "ActHIB", "type": "BIOLOGICAL" }, { "name": "PedvaxHIB", "type": "BIOLOGICAL" }, { "name": "Pediarix", "type": "BIOLOGICAL" }, { "name": "Prevnar", "type": "BIOLOGICAL" }, { "name": "M-M-R II", "type": "BIOLOGICAL" }, { "name": "Varivax", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "15 Months", "sex": "ALL", "summary": "6 Weeks to 15 Months" }, "enrollment_count": 4441, "start_date": "2006-02-22", "completion_date": "2008-02-26", "has_results": true, "last_update_posted_date": "2018-08-24", "last_synced_at": "2026-09-05T20:21:45.501Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00289783" }, { "nct_id": "NCT05622682", "title": "Vaccine Immune Recovery After Leukemia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Lymphoblastic Leukemia, Pediatric" ], "interventions": [ { "name": "Observational only: Serology and flow cytometry for ALL cohort participants", "type": "OTHER" }, { "name": "Observational only: Infection rates", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "31 Years", "sex": "ALL", "summary": "3 Years to 31 Years" }, "enrollment_count": 89, "start_date": "2022-09-28", "completion_date": "2025-11-30", "has_results": true, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-09-05T20:21:45.501Z", "location_count": 6, "location_summary": "Chicago, Illinois • Grand Rapids, Michigan • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05622682" }, { "nct_id": "NCT04209660", "title": "Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenoid Cystic Carcinoma", "Salivary Gland Cancer" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2020-06-02", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-09-05T20:21:45.501Z", "location_count": 8, "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04209660" }, { "nct_id": "NCT06295731", "title": "INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)" ], "interventions": [ { "name": "INBRX-106", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 410, "start_date": "2024-05-14", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-09-05T20:21:45.501Z", "location_count": 25, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 22 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06295731" }, { "nct_id": "NCT04333732", "title": "CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID 19" ], "interventions": [ { "name": "MR or M-M-R II ® vaccine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3411, "start_date": "2020-09-04", "completion_date": "2021-12-03", "has_results": true, "last_update_posted_date": "2024-03-26", "last_synced_at": "2026-09-05T20:21:45.501Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04333732" } ] }